Zydus Lifesciences Limited

BSE: ZYDUSLIFE532321ISIN INE010B01027

Healthcare
Pharmaceuticals
BSE 200

Share price

₹1,190.00-49.00 (-3.95%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,266.15
52W low: ₹835.85
Off 52W high: -6.01%
1M return: +4.52%
3M return: +7.11%
6M return: +26.72%
1Y return: +22.32%
20D avg volume: 94,748
50 DMA: ₹1,153.50
200 DMA: ₹1,037.27

Key ratios Consolidated

Market cap: ₹1,18,703 Cr
Current price: ₹1,190.00
52W high / low: ₹1,266.15 / ₹835.85
Face value: ₹1.00
P/E: 25.85
P/B: 4.42
EPS (TTM): ₹46.04
Book value / share: ₹269.50
ROE: —
ROCE: 19.20%
Operating margin: —
Net margin: —
Debt / equity: 0.40
Net debt: ₹10,914 Cr
Interest cover: 16.09
Dividend yield: 0.08%
Dividend / share (TTM): ₹1.00
Payout: 2.17%
Cash conversion cycle: 110.2 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	8,017	7,587	6,864	6,123	6,574	6,528	5,269	5,237	6,208	5,534	4,505	4,369
	106.10	134.20	111.40	109.00	154.90	80.60	57.50	68.20	63.20	156.40	37.70	54.00
	8,123	7,721	6,976	6,232	6,729	6,608	5,327	5,305	6,271	5,690	4,543	4,423
	6,798	5,664	5,538	4,511	4,808	4,717	4,142	4,034	4,371	4,143	3,617	3,416
	1,251	1,347	1,216	1,327	1,219	1,164	1,026	1,066	1,116	1,210	1,063	1,037
	1,289	971.70	851.50	589.10	658.20	572.60	571.10	483.90	522.40	542.90	459.40	405.50
	1,368	1,239	1,140	1,034	1,005	971.40	946.50	879.20	883.50	837.00	817.30	752.90
	156.00	123.00	129.90	101.30	84.70	76.60	32.00	25.10	32.20	34.60	19.80	8.70
	554.70	508.40	359.60	301.90	238.10	237.90	229.00	233.60	215.30	205.30	194.80	184.20
	2,480	1,818	2,072	1,383	1,690	1,734	1,534	1,470	1,629	1,460	1,138	1,078
	1,325	2,057	1,438	1,722	1,921	1,892	1,184	1,271	1,900	1,547	925.50	1,007
	-18.20	-397.50	-84.90	-34.20	0.00	-219.60	0.00	0.00	0.00	0.00	0.00	0.00
	1,307	1,660	1,353	1,687	1,921	1,672	1,184	1,271	1,900	1,547	925.50	1,007
	354.20	318.40	388.30	454.00	434.00	423.20	179.50	373.10	436.10	321.20	213.80	226.40
	990.20	1,341	1,023	1,239	1,521	1,244	1,026	920.20	1,482	1,246	789.90	803.20
	9.35	12.65	10.36	12.51	14.58	11.64	10.18	9.05	14.11	11.66	7.59	7.92
Key metrics
	2,017	2,291	1,843	2,091	2,243	1,986	1,445	1,530	2,147	1,787	1,140	1,200
	25.20%	30.20%	26.80%	34.10%	34.10%	30.40%	27.40%	29.20%	34.60%	32.30%	25.30%	27.50%
	12.40%	17.70%	14.90%	20.20%	23.10%	19.10%	19.50%	17.60%	23.90%	22.50%	17.50%	18.40%
	—	4.90%	—	4.80%	—	6.20%	—	—	—	—	—	—
	22.00%	16.20%	30.30%	16.90%	5.90%	18.00%	17.00%	19.90%	—	—	—	—
	-34.90%	7.80%	-0.30%	34.60%	2.60%	-0.20%	29.90%	14.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	28,592	27,148	23,242	19,547	17,237	15,265	15,102	14,253	13,166	11,936	9,625
	460.70	509.50	269.50	284.10	186.60	224.70	37.20	113.90	201.10	113.20	128.60
	29,052	27,658	23,511	19,832	17,424	15,490	15,139	14,367	13,367	12,050	9,754
	22,510	20,520	17,265	15,008	14,230	12,764	12,650	12,508	10,985	9,719	8,142
	5,142	5,110	4,373	4,580	4,123	4,043	3,888	3,460	2,674	2,555	1,831
	3,702	3,070	2,150	1,898	1,949	1,865	1,471	1,554	2,152	1,914	1,753
	4,781	4,418	3,681	3,138	2,766	2,434	2,490	2,414	2,124	1,854	—
	510.20	438.90	165.90	81.20	129.90	127.00	163.50	341.80	193.50	91.10	45.00
	1,725	1,408	915.80	764.10	722.70	713.00	724.80	696.50	598.60	—	375.00
	7,752	6,963	6,164	4,878	4,586	3,945	4,061	4,135	3,352	3,081	2,581
	6,542	7,138	6,246	4,823	3,194	2,725	2,490	1,859	2,382	2,331	1,612
	-534.80	-516.60	-219.60	-14.20	-604.20	112.70	-205.10	-363.60	0.00	0.00	-0.30
	6,007	6,621	6,027	4,809	2,590	2,838	2,285	1,495	2,382	2,331	1,612
	1,515	1,595	1,412	977.50	587.80	511.70	147.20	319.80	530.30	564.40	128.90
	4,593	5,124	4,673	3,973	2,092	4,618	2,185	1,204	1,899	1,810	1,517
	44.87	50.09	44.97	37.91	19.35	21.90	20.84	11.49	18.06	—	—
Key metrics
	8,242	8,468	7,108	5,654	3,442	3,678	3,173	2,534	3,174	2,422	2,032
	28.83%	31.20%	30.60%	28.90%	20.00%	24.10%	21.00%	17.80%	24.10%	20.30%	21.10%
	16.06%	18.90%	20.10%	20.30%	12.10%	30.30%	14.50%	8.50%	14.40%	15.20%	15.80%
	—	19.20%	22.00%	—	—	—	—	—	—	—	—
	21.11%	16.80%	18.90%	13.40%	12.90%	1.10%	6.00%	8.30%	10.30%	24.00%	—
	-2.51%	9.60%	17.60%	89.90%	-54.70%	111.40%	81.40%	-36.60%	4.90%	19.40%	—
	—	-1,277	5,064	—	—	—	—	—	—	—	—
	—	0.41	1.45	—	—	—	—	—	—	—	—
	—	0.40	0.12	—	—	—	—	—	—	—	—
	—	10,914	2,343	—	—	—	—	—	—	—	—
	—	110.2	88.9	—	—	—	—	—	—	—	—
Balance sheet
	—	52,407	37,202	—	—	—	—	—	—	—	—
	—	19,906	17,046	—	—	—	—	—	—	—	—
	—	855.20	826.80	—	—	—	—	—	—	—	—
	—	5,416	4,025	—	—	—	—	—	—	—	—
	—	5,628	3,944	—	—	—	—	—	—	—	—
	—	1,449	679.40	—	—	—	—	—	—	—	—
	—	9,231	6,042	—	—	—	—	—	—	—	—
	—	2,845	2,306	—	—	—	—	—	—	—	—
	—	15,712	9,042	—	—	—	—	—	—	—	—
	—	11,770	3,170	—	—	—	—	—	—	—	—
	—	8,582	3,170	—	—	—	—	—	—	—	—
	—	3,188	0.00	—	—	—	—	—	—	—	—
	—	29,582	26,358	—	—	—	—	—	—	—	—
Cash flow
	—	2,117	6,777	—	—	—	—	—	—	—	—
	—	-8,296	-8,372	—	—	—	—	—	—	—	—
	—	5,997	2,031	—	—	—	—	—	—	—	—
	—	3,394	1,713	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,872	3,741	2,284	2,871	2,588	5,820	2,516	2,621	4,160	3,332	2,371	2,159
	123.70	495.10	473.80	541.50	157.10	185.40	77.50	326.70	106.60	361.10	106.80	534.50
	2,996	4,236	2,757	3,413	2,745	6,005	2,593	2,947	4,267	3,694	2,478	2,694
	2,540	2,018	2,345	1,969	2,270	2,330	2,096	1,908	2,033	2,000	1,904	1,726
	861.50	936.70	849.50	890.80	853.70	720.80	635.80	704.80	725.70	737.20	681.60	705.90
	198.20	68.90	28.20	44.50	56.10	93.00	112.10	87.10	58.70	71.10	68.70	99.50
	561.40	513.90	496.40	468.70	487.20	476.30	425.00	436.50	424.40	405.10	373.00	377.70
	103.10	115.50	116.00	113.80	137.60	155.40	97.20	95.90	115.40	106.20	103.90	90.90
	151.90	150.90	144.30	136.00	130.00	128.00	131.60	133.70	130.60	130.60	127.70	124.90
	880.80	288.50	707.60	407.60	611.90	880.40	717.80	643.50	619.60	643.70	541.20	511.60
	455.70	2,218	412.50	1,444	474.90	3,675	497.20	1,039	2,234	1,694	574.30	968.10
	0.00	-106.80	-60.10	0.00	0.00	0.00	—	—	—	-8.60	—	—
	455.70	2,111	352.40	1,444	474.90	3,675	497.20	1,039	2,234	1,685	574.30	968.10
	116.10	389.00	55.90	287.00	90.20	861.00	26.60	249.50	532.70	279.70	123.90	163.10
	339.60	1,722	296.50	1,157	384.70	2,814	470.60	789.80	1,701	1,405	450.40	805.00
	3.38	17.11	2.95	11.49	3.82	27.96	4.68	7.85	16.90	13.89	4.45	7.96
Key metrics
	710.70	2,377	612.70	1,693	742.50	3,958	726.00	1,269	2,480	1,922	805.90	1,184
	24.70%	63.60%	26.80%	59.00%	28.70%	68.00%	28.90%	48.40%	59.60%	57.70%	34.00%	54.80%
	11.80%	46.00%	13.00%	40.30%	14.90%	48.30%	18.70%	30.10%	40.90%	42.20%	19.00%	37.30%
	—	7.90%	—	6.10%	—	15.70%	—	—	—	—	—	—
	11.00%	-35.70%	-9.20%	9.60%	-37.80%	74.60%	6.10%	21.40%	—	—	—	—
	-11.70%	-38.80%	-37.00%	46.40%	-77.40%	100.20%	4.50%	-1.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	11,768	11,484	15,116	10,819	8,732	7,982	7,790	6,347	6,493	5,823	3,274
	1,634	1,668	696.20	1,085	548.40	178.70	78.90	849.40	611.60	207.90	583.10
	13,402	13,152	15,812	11,904	9,280	8,161	7,869	7,197	7,104	6,030	3,858
	8,872	8,603	8,368	7,655	7,044	6,677	5,993	5,587	5,176	4,533	3,215
	3,538	3,531	2,787	3,001	2,704	2,629	2,346	1,838	1,830	1,577	926.70
	339.80	197.70	350.90	283.20	362.70	288.10	153.30	97.90	390.60	318.60	228.80
	2,040	1,966	1,762	1,508	1,322	1,205	1,147	1,077	974.50	826.00	620.80
	448.40	482.90	463.90	390.70	278.20	134.90	70.90	233.90	88.40	63.90	11.10
	583.10	561.20	523.90	504.40	488.60	478.70	451.10	428.90	349.80	293.10	250.90
	2,284	2,016	2,601	2,174	—	1,989	1,973	1,895	1,615	1,642	1,280
	4,530	4,549	7,445	4,248	2,236	1,483	1,876	1,610	1,928	1,497	642.20
	-166.90	-166.90	0.00	-8.60	-203.80	-319.30	-187.50	-52.00	—	—	—
	4,363	4,382	7,445	4,240	2,032	1,164	1,688	1,558	1,928	1,497	642.20
	848.00	822.10	1,670	798.30	503.00	306.00	212.30	204.10	326.40	406.40	19.70
	3,515	3,560	5,775	3,442	1,529	857.90	1,476	1,413	1,602	1,091	661.90
	34.93	35.38	57.39	34.01	15.06	8.38	14.42	13.22	15.65	—	—
Key metrics
	5,394	5,426	8,432	5,135	2,799	1,778	2,210	2,220	2,367	1,854	904.20
	45.84%	47.20%	55.80%	47.50%	32.10%	22.30%	28.40%	35.00%	36.50%	31.80%	27.60%
	29.87%	31.00%	38.20%	31.80%	17.50%	10.70%	18.90%	22.30%	24.70%	18.70%	20.20%
	—	17.20%	32.30%	—	—	—	—	—	—	—	—
	-13.12%	-24.00%	39.70%	23.90%	9.40%	2.50%	22.70%	-2.20%	11.50%	77.80%	—
	-21.17%	-38.40%	67.80%	125.10%	78.20%	-41.90%	4.50%	-11.80%	46.90%	64.80%	—
	—	1,335	2,209	—	—	—	—	—	—	—	—
	—	0.63	0.54	—	—	—	—	—	—	—	—
	—	0.31	0.39	—	—	—	—	—	—	—	—
	—	7,104	8,236	—	—	—	—	—	—	—	—
	—	292.4	214.5	—	—	—	—	—	—	—	—
Balance sheet
	—	33,880	32,317	—	—	—	—	—	—	—	—
	—	16,252	15,315	—	—	—	—	—	—	—	—
	—	327.00	103.00	—	—	—	—	—	—	—	—
	—	8,495	8,162	—	—	—	—	—	—	—	—
	—	2,178	1,952	—	—	—	—	—	—	—	—
	—	545.90	280.40	—	—	—	—	—	—	—	—
	—	5,011	4,136	—	—	—	—	—	—	—	—
	—	1,472	1,232	—	—	—	—	—	—	—	—
	—	5,593	7,851	—	—	—	—	—	—	—	—
	—	7,431	8,339	—	—	—	—	—	—	—	—
	—	3,198	5,477	—	—	—	—	—	—	—	—
	—	4,233	2,862	—	—	—	—	—	—	—	—
	—	23,672	21,190	—	—	—	—	—	—	—	—
Cash flow
	—	2,234	3,114	—	—	—	—	—	—	—	—
	—	569.60	-4,504	—	—	—	—	—	—	—	—
	—	-2,580	1,384	—	—	—	—	—	—	—	—
	—	899.00	904.90	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +9.56%
Sales CAGR 5Y: +8.07%
Profit CAGR 3Y: +32.53%
Profit CAGR 5Y: +19.25%
Sales YoY (TTM): -13.12%
Profit YoY (TTM): -21.17%

Consolidated

Sales CAGR 3Y: +16.35%
Sales CAGR 5Y: +12.45%
Profit CAGR 3Y: +34.80%
Profit CAGR 5Y: +18.58%
Sales YoY (TTM): +21.11%
Profit YoY (TTM): -2.51%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 74.99%

Quarter	September 2026	June 2026
Promoter %	74.99%	74.99%

Holder	Type	Holding	Previous	Change
Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees)	Promoter	74.98%	74.98%	0.00%
Life Insurance Corporation Of India	Public	3.77%	5.41%	-1.64%
Parag Parikh Flexi Cap Fund	Public	2.01%	2.02%	-0.01%
Quant Mutual Fund - Quant Multi Cap Fund	Public	1.49%	—	—
Kotak Flexicap Fund	Public	1.07%	1.19%	-0.12%
Arati Rajiv Mehta	Promoter Group	0.01%	0.01%	0.00%
Western Ahmedabad Effluent Conveyance Company Private Limited	Promoter Group	0.00%	0.00%	0.00%
Pankaj Ramanbhai Patel HUF (Pankaj Ramanbhai Patel-Karta)	Promoter Group	0.00%	0.00%	0.00%
Shivani Pankajbhai Patel	Promoter Group	0.00%	0.00%	0.00%
Sharvil P. Patel HUF	Promoter Group	0.00%	0.00%	0.00%
Cadmach Machinery Company Private Limited	Promoter Group	0.00%	0.00%	0.00%
Zandra Infrastructure LLP	Promoter Group	0.00%	0.00%	0.00%
Cadila Lifesciences Private Limited	Promoter Group	0.00%	0.00%	0.00%
Meha Sharvil Patel	Promoter Group	0.00%	0.00%	0.00%
Shaurya Sharvil Patel	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Newspaper publication of notice of loss of share certificate of the Company published in the Financial Express English and Gujarati editions, both on November 4, 2026.4 Nov 2026 · Company Update / Newspaper Publication
Press Release4 Nov 2026 · Company Update / Press Release / Media Release
Investor presentation4 Nov 2026 · Company Update / Investor Presentation
Appointment of statutory auditors pursuant to mandatory auditor rotation4 Nov 2026 · Company Update / Appointment of Statutory Auditor/s
Outcome of Board Meeting held on November 4, 20264 Nov 2026 · Board Meeting / Outcome of Board Meeting
Unaudited Financial Results for the quarter and half year ended on September 30, 20264 Nov 2026 · Result / Financial Results
Update on acquisition of API business2 Nov 2026 · Company Update / Acquisition
Changes in Senior Management team31 Oct 2026 · Company Update / Change in Management
The newspaper publication of notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on October 30, 2026.30 Oct 2026 · Company Update / Newspaper Publication
Q2 FY27 post results earning call details24 Oct 2026 · Company Update / Analyst / Investor Meet
Zylidac Bio and Prolific Machines Partner to Scale Prolific''s Next-Generation Biologics Manufacturing Platform to GMP Production.21 Oct 2026 · Company Update / Press Release / Media Release
Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity.21 Oct 2026 · Company Update / Press Release / Media Release
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve unaudited financial results ....19 Oct 2026 · Board Meeting / Board Meeting
ESG Rating16 Oct 2026 · Company Update / General
Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka.15 Oct 2026 · Company Update / Press Release / Media Release
USFDA Inspection13 Oct 2026 · Company Update / Press Release / Media Release
Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by UDFDA.13 Oct 2026 · Company Update / Press Release / Media Release
Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across ....12 Oct 2026 · Company Update / Press Release / Media Release
Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026.6 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Zydus, MSN partner to Launch First Generic of Adempas (Riociguat Tablets) in the U.S.5 Oct 2026 · Company Update / Press Release / Media Release
Extension of date of closing1 Oct 2026 · Company Update / Joint Venture
USFDA inspection concludes at Zydus'' manufacturing plant at SEZ II, Ahmedabad.28 Sep 2026 · Company Update / Press Release / Media Release
Intimation of Trading Window Closure26 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
USFDA inspection of pharmacovigilance and post marketing system concludes at Zydus'' USA Office with nil observations.26 Sep 2026 · Company Update / Press Release / Media Release
Newspaper publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on September 24, 2026.24 Sep 2026 · Company Update / Newspaper Publication
Newspaper publication of Notice of opening of Special Window for transfer and dematerialization of physical securities, published in the Financial Express English and Gujarati editions, ....22 Sep 2026 · Company Update / Newspaper Publication
Credit Rating11 Sep 2026 · Company Update / Credit Rating
The Company is going to participate in J.P. Morgan India Conference, 2026, on September 21, 2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Newspaper publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on September 9, 2026.9 Sep 2026 · Company Update / Newspaper Publication
Settlement Agreement5 Sep 2026 · Company Update / General
Transcript of the 31st Annual General Meeting1 Sep 2026 · AGM/EGM / AGM
Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH.31 Aug 2026 · Company Update / Press Release / Media Release
Incorporation of a wholly owned subsidiary in Gift City, Gandhinagar, Gujarat26 Aug 2026 · Company Update / General
ESG Rating25 Aug 2026 · Company Update / General
Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 201524 Aug 2026 · Company Update / General
Investor Presentation23 Aug 2026 · Company Update / Investor Presentation
ESG Rating21 Aug 2026 · Company Update / General
Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.21 Aug 2026 · Company Update / Press Release / Media Release
Transcript of the post results earnings call held on August 11, 202618 Aug 2026 · Company Update / Earnings Call Transcript
The management of the Company will meet the investors in Singapore and Hong Kong between August 24, 2026, to August 26, 2026, in the form of a Non-Deal Roadshow (NDR).17 Aug 2026 · Company Update / Analyst / Investor Meet

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.0000	24 Jul 2026	24 Jul 2026	—
Buy Back of Shares	29 May 2026	29 May 2026	—
Final Dividend - Rs. - 11.0000	25 Jul 2025	25 Jul 2025	—
Final Dividend - Rs. - 3.0000	26 Jul 2024	26 Jul 2024	—

Board meetings

4 Nov 2026 Board Meeting - Financial Results
11 Aug 2026 Board Meeting - Financial Results